0OT Stock Overview A biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Ocular Therapeutix, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Ocular Therapeutix Historical stock prices Current Share Price US$8.04 52 Week High US$10.95 52 Week Low US$3.47 Beta 1.2 1 Month Change -4.12% 3 Month Change 5.59% 1 Year Change 118.71% 3 Year Change 31.87% 5 Year Change 118.59% Change since IPO -14.72%
Recent News & Updates
Ocular Therapeutix Announces More Than 300 Subjects Randomized in Sol-1 Dec 03
New minor risk - Insider selling Nov 17
Third quarter 2024 earnings released: US$0.22 loss per share (vs US$0.006 loss in 3Q 2023) Nov 16
Ocular Therapeutix, Inc. Appoints Namrata Saroj, OD, as Chief Business Officer Nov 12
Ocular Therapeutix, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Nov 07
Ocular Therapeutix, Inc. Announces Accelerated Timelines for Sol-1 Registrational Trial of AXPAXLI in Wet AMD Oct 15 See more updates
Ocular Therapeutix Announces More Than 300 Subjects Randomized in Sol-1 Dec 03
New minor risk - Insider selling Nov 17
Third quarter 2024 earnings released: US$0.22 loss per share (vs US$0.006 loss in 3Q 2023) Nov 16
Ocular Therapeutix, Inc. Appoints Namrata Saroj, OD, as Chief Business Officer Nov 12
Ocular Therapeutix, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Nov 07
Ocular Therapeutix, Inc. Announces Accelerated Timelines for Sol-1 Registrational Trial of AXPAXLI in Wet AMD Oct 15
Now 22% undervalued Sep 25
Now 23% undervalued Aug 30
Executive Chairman recently sold €168k worth of stock Aug 30
Second quarter 2024 earnings released: US$0.26 loss per share (vs US$0.27 loss in 2Q 2023) Aug 08
Ocular Therapeutix, Inc. Announces Fda Feedback That Sol-R Trial Is Appropriate as A Registrational Study in Wet Amd Aug 07
Ocular Therapeutix, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Jul 31
Ocular Therapeutix, Inc. Announces First Patients Enrolled in Phase 3 Sol-R Wet AMD Study Jul 30
Executive Chairman recently sold €116k worth of stock May 29
First quarter 2024 earnings released: US$0.49 loss per share (vs US$0.39 loss in 1Q 2023) May 08
Ocular Therapeutix, Inc. to Report Q1, 2024 Results on May 07, 2024 May 03
Ocular Therapeutix, Inc., Annual General Meeting, Jun 12, 2024 May 01
Ocular Therapeutix, Inc. Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy Apr 19 Ocular Therapeutix, Inc. Announces CEO Changes
Ocular Therapeutix, Inc. Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting Apr 08
New major risk - Shareholder dilution Mar 12
Full year 2023 earnings released: US$1.01 loss per share (vs US$0.92 loss in FY 2022) Mar 12 Ocular Therapeutix, Inc. to Report Q4, 2023 Results on Mar 11, 2024 Ocular Therapeutix, Inc. Announces Management Changes
AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA Feb 20
Ocular Therapeutix, Inc. Appoints Steve Meyers as Chief Commercial Officer Feb 15
President recently sold €84k worth of stock Feb 05
Ocular Therapeutix Announces FDA Agreement to Amend Special Protocol Assessment (Spa) for Pivotal Clinical Trial of Axpaxli in Wet AMD Jan 25 Ocular Therapeutix, Inc. has completed a Follow-on Equity Offering in the amount of $100.1 million. Dec 15
Ocular Therapeutix, Inc. has completed a Follow-on Equity Offering in the amount of $100.1 million.
New minor risk - Profitability Nov 09
Ocular Therapeutix, Inc. Provides Earnings Guidance for the Full Year 2023 Nov 08
Third quarter 2023 earnings released: US$0.006 loss per share (vs US$0.31 loss in 3Q 2022) Nov 08
Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD Nov 02
AffaMed Therapeutics Announces Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Patients after Cataract Surgery Nov 01
Ocular Therapeutix, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 25
Ocular Therapeutix, Inc. Announces Initiation of Its First Pivotal Clinical Trial of OTX-TKI in Wet AMD Oct 05
Ocular Therapeutix, Inc. Submits Request for Special Protocol Assessment to the U.S. Food and Drug Administration Sep 14
New minor risk - Financial position Aug 13
Second quarter 2023 earnings released: US$0.27 loss per share (vs US$0.24 loss in 2Q 2022) Aug 08
Ocular Therapeutix, Inc. to Report Q2, 2023 Results on Aug 07, 2023 Jul 25
Ocular Therapeutix™ Announces Appointment of Adrienne L. Graves as New Board Member Jul 13
New major risk - Share price stability Jun 15
Ocular Therapeutix, Inc. Completes Enrollment of the Helios Clinical Trial of OTX-TKI for the Treatment of Diabetic Retinopathy Jun 08
Ocular Therapeutix, Inc. Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI Jun 06
Ocular Therapeutix, Inc. Provides Earnings Guidance for the Year 2023 May 10
First quarter 2023 earnings released: US$0.39 loss per share (vs US$0.16 loss in 1Q 2022) May 09
Full year 2022 earnings released: US$0.92 loss per share (vs US$0.086 loss in FY 2021) Mar 08
Ocular Therapeutix™ Announces Interim 10-Month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD Feb 12
Insufficient new directors Nov 16
Third quarter 2022 earnings released: US$0.31 loss per share (vs US$0.035 profit in 3Q 2021) Nov 09
Ocular Therapeutix, Inc. Provides Earnings Guidance for the Fiscal Year 2022 Nov 08
Ocular Therapeutix, Inc. to Report Q3, 2022 Results on Nov 07, 2022 Oct 25
Ocular Therapeutix, Inc. Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD Sep 28
Ocular Therapeutix, Inc. Provides Revenue Guidance for the Full Year 2022 Aug 10
Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.11 loss in 2Q 2021) Aug 09
Insufficient new directors Aug 01
Ocular Therapeutix, Inc. to Report Q2, 2022 Results on Aug 08, 2022 Jul 26
Insufficient new directors Jul 02
Ocular Therapeutix, Inc. Announces Executive Changes Jun 10
Ocular Therapeutix, Inc. Announces Executive Changes Jun 09
First quarter 2022 earnings released: US$0.16 loss per share (vs US$0.041 profit in 1Q 2021) May 11 Ocular Therapeutix, Inc. Provides Earnings Guidance for the Full Year 2022 May 10
Ocular Therapeutix, Inc., Annual General Meeting, Jun 16, 2022 May 03
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 02
Ocular Therapeutix, Inc. to Report Q4, 2021 Results on Feb 28, 2022 Feb 24
Ocular Therapeutix, Inc. Announces Resignation of Bruce A. Peacock as Member of the Board of Directors Feb 08
Third quarter 2021 earnings released: EPS US$0.035 (vs US$0.19 loss in 3Q 2020) Nov 09
Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.64 loss in 2Q 2020) Aug 10
Ocular Therapeutix, Inc. Provides Earnings Guidance for the Second Quarter Ended June 30, 2021 Jul 25
Independent Director recently sold €117k worth of stock May 23
First quarter 2021 earnings released: EPS US$0.041 (vs US$0.41 loss in 1Q 2020) May 06
Ocular Therapeutix Fulfills Post-Marketing Approval Requirements for ReSure Sealant May 05
Chief Operating Officer has left the company May 05
Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting Apr 30 Shareholder Returns 0OT DE Pharmaceuticals DE Market 7D -1.6% -2.2% -2.0% 1Y 118.7% -15.6% 6.9%
See full shareholder returns
Return vs Market: 0OT exceeded the German Market which returned 6.9% over the past year.
Price Volatility Is 0OT's price volatile compared to industry and market? 0OT volatility 0OT Average Weekly Movement 8.0% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 0OT's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 0OT's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease.
Show more Ocular Therapeutix, Inc. Fundamentals Summary How do Ocular Therapeutix's earnings and revenue compare to its market cap? 0OT fundamental statistics Market cap €1.28b Earnings (TTM ) -€167.09m Revenue (TTM ) €58.89m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0OT income statement (TTM ) Revenue US$61.44m Cost of Revenue US$108.62m Gross Profit -US$47.18m Other Expenses US$127.16m Earnings -US$174.34m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.11 Gross Margin -76.79% Net Profit Margin -283.74% Debt/Equity Ratio 19.3%
How did 0OT perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 12:30 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Ocular Therapeutix, Inc. is covered by 21 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Colleen Kusy Baird Anita Dushyanth Berenberg Tazeen Ahmad BofA Global Research
Show 18 more analysts 
